| Dr Bryan C Kavanaugh, MD | |
|
2940 N Circle Dr, Colorado Springs, CO 80909-1160 | |
| (719) 635-7321 | |
| (719) 635-2510 |
| Full Name | Dr Bryan C Kavanaugh |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 21 Years |
| Location | 2940 N Circle Dr, Colorado Springs, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346452273 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | DR0048818 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centura Health-penrose St Francis Health Services | Colorado springs, CO | Hospital |
| Heart Of The Rockies Regional Medical Center | Salida, CO | Hospital |
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Assoc In Gastroenterology, Pc | 7416925052 | 19 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Salida Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972778272 PECOS PAC ID: 3577451152 Enrollment ID: O20040413000292 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Assoc In Gastroenterology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184791279 PECOS PAC ID: 7416925052 Enrollment ID: O20040921000793 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Salida Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1730258971 PECOS PAC ID: 3577451152 Enrollment ID: O20081209000720 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Optumcare Colorado Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407252828 PECOS PAC ID: 2769706431 Enrollment ID: O20150129000413 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Eccs Acquisition Company Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1114584786 PECOS PAC ID: 2264868272 Enrollment ID: O20200212000183 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Entity Name | Eccs Acquisition Company Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1912678947 PECOS PAC ID: 2264868272 Enrollment ID: O20211018000852 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bryan C Kavanaugh, MD 2940 N Circle Dr, Colorado Springs, CO 80909-1160 Ph: (719) 635-7321 | Dr Bryan C Kavanaugh, MD 2940 N Circle Dr, Colorado Springs, CO 80909-1160 Ph: (719) 635-7321 |
News Archive
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university.
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.
› Verified 8 days ago
Michael Judd Burkholz, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2940 N Circle Dr, Colorado Springs, CO 80909 Phone: 719-635-7321 Fax: 719-635-2510 | |
Mrs. Rachel Elizabeth Black, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 2222 N Nevada Ave Ste 4004, Colorado Springs, CO 80907 Phone: 719-471-7064 | |
William A Munson, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 325 E Fontanero St, Colorado Springs Endocrine Clinic Pc, Colorado Springs, CO 80907 Phone: 719-636-3829 Fax: 719-636-1387 | |
Barbara E Johnston, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 175 S Union Blvd Ste 350, Colorado Springs, CO 80910 Phone: 719-633-5515 Fax: 719-365-1307 | |
Dr. Raymond L. Wahl, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2502 E Pikes Peak Ave, Colorado Springs, CO 80909 Phone: 719-630-6440 Fax: 719-228-6603 | |
Dr. Duane Ryan Spaulding, M.D., F.A.C.P. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 6722 Northface Ln, Colorado Springs, CO 80919 Phone: 719-590-9338 | |
Dr. Wendy Marie Bamberg, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 301 S Union Blvd, Colorado Springs, CO 80910 Phone: 719-578-3199 |